MIRM Mirum Pharmaceuticals, Inc.
Biotechnology NasdaqGM
Trading Signals (MIRM)
Overall Signal
BUY
Strong buyish signal based on multiple indicators.
Key Price Levels
Support Levels
- Strong Support $47.2
- Medium Support $48.69
- Weak Support $50.19
Resistance Levels
- Weak Resistance $53.17
- Medium Resistance $54.67
- Strong Resistance $56.16
Stop Loss Suggestions
- Conservative $50.48
- Moderate $49.44
- Aggressive $47.94
Analyst Ratings
Current Rating
Signal Indicator
| Indicator | Signal | Strength | Timeframe |
|---|---|---|---|
| Moving Averages | NEUTRAL |
|
Short & Medium Term |
| Oscillators | BUY |
|
Short Term |
| Trend Indicators | SELL |
|
Short & Medium Term |
| Volume Indicators | BUY |
|
Short & Medium Term |
| Support/Resistance | NEUTRAL |
|
Short Term |
Stock Price Prediction Price Target Probabilities (MIRM)
Quarterly Outlook :
2025-12-17
Bullish Scenario
from current 14.27%
Strong upward momentum and confirmed bullish trend, with potential for significant price appreciation. Indicators point to sustained buying pressure. ADX (28.32) indicates a strong trend. +DI > -DI suggests strong bullish directional bias. RSI (61.76) is in bullish territory, indicating upward momentum. MACD line (2.11) is above Signal line (2.02) (bullish crossover), confirming upward momentum. Both lines are above zero, reinforcing bullish trend. Current Weekly ATR is 2.95, indicating the average weekly price range.
2025-12-17
Base Scenario
from current 5.71%
Price is likely to continue its moderate trajectory, reflecting underlying market conditions and historical volatility. Indicators suggest a balanced outlook. ADX (28.32) indicates a strong trend. +DI > -DI suggests strong bullish directional bias. RSI (61.76) is in bullish territory, indicating upward momentum. MACD line (2.11) is above Signal line (2.02) (bullish crossover), confirming upward momentum. Both lines are above zero, reinforcing bullish trend. Current Weekly ATR is 2.95, indicating the average weekly price range.
2025-12-17
Bearish Scenario
from current -11.42%
Increased selling pressure and potential for a significant price correction or downtrend. Indicators suggest waning bullish momentum or strengthening bearish forces. ADX (28.32) indicates a strong trend. +DI > -DI suggests strong bullish directional bias. RSI (61.76) is in bullish territory, indicating upward momentum. MACD line (2.11) is above Signal line (2.02) (bullish crossover), confirming upward momentum. Both lines are above zero, reinforcing bullish trend. Current Weekly ATR is 2.95, indicating the average weekly price range.
Annual Outlook
2025-12-17
Bullish Scenario
from current 28.54%
Long-term bullish trend with strong fundamental catalysts and sustained institutional buying. Expect significant capital appreciation over the year. ADX (28.32) indicates a strong trend. +DI > -DI suggests strong bullish directional bias. RSI (61.76) is in bullish territory, indicating upward momentum. MACD line (2.11) is above Signal line (2.02) (bullish crossover), confirming upward momentum. Both lines are above zero, reinforcing bullish trend. Current Weekly ATR is 2.95, indicating the average weekly price range.
2025-12-17
Base Scenario
from current 11.42%
Steady long-term growth consistent with market and industry averages. Price expected to follow a typical growth trajectory. ADX (28.32) indicates a strong trend. +DI > -DI suggests strong bullish directional bias. RSI (61.76) is in bullish territory, indicating upward momentum. MACD line (2.11) is above Signal line (2.02) (bullish crossover), confirming upward momentum. Both lines are above zero, reinforcing bullish trend. Current Weekly ATR is 2.95, indicating the average weekly price range.
2025-12-17
Bearish Scenario
from current -22.83%
Long-term bearish trend with significant headwinds from economic factors, industry disruption, or company-specific issues. Expect notable price depreciation. ADX (28.32) indicates a strong trend. +DI > -DI suggests strong bullish directional bias. RSI (61.76) is in bullish territory, indicating upward momentum. MACD line (2.11) is above Signal line (2.02) (bullish crossover), confirming upward momentum. Both lines are above zero, reinforcing bullish trend. Current Weekly ATR is 2.95, indicating the average weekly price range.
Technical Analysis (MIRM)
Trend Identification
EMA
Exponential Moving Average
Current price (51.68) is between Short MA (51.98) and Long MA (48.49), or near one of them. This suggests consolidation or mixed signals. Short MA (51.98) is above Long MA (48.49), a bullish crossover ('Golden Cross' if it's a significant period). This indicates an upward trend. MAs (51.98, 48.49, 46.28) show mixed alignment, suggesting market indecision or range-bound activity. Market is in a choppy or sideways phase. Wait for a clearer trend to emerge before taking directional trades.
MACD
Moving Average Convergence Divergence
MACD line is below the Signal line (bearish crossover). This indicates downward momentum. Histogram (-0.3200) is negative and expanding, confirming bearish momentum. Both MACD and Signal lines are above the zero line, reinforcing bullish momentum (bullish territory). A bearish crossover above the zero line can indicate a reversal from a prior uptrend. Consider this as a potential early sell signal.
ADX
Average Directional Index
ADX (19.73) indicates a weak or non-existent trend (ranging market). +DI (19.77) is above -DI (17.39), suggesting a bullish directional bias. Avoid trend-following strategies. Consider range-bound or reversal strategies, or wait for a clearer trend to develop.
Momentum Measurement
RSI (2025-12-17)
Relative Strength Index
RSI (53.63) is in the bullish territory, but not yet overbought. This indicates upward momentum. Monitor for continuation or signs of weakness.
OBV (2025-12-17)
On-Balance Volume
OBV (5078633.00) is rising, indicating buying pressure and accumulation. Price is rising and OBV is rising. This is bullish confirmation, indicating buying pressure supports the price increase. Consider holding long positions or initiating new ones. Volume is supporting the trend.
Stochastic (2025-12-17)
Stochastic Oscillator
Stochastics (%K: 21.84, %D: 17.66) are in the neutral zone (between 20 and 80). A bullish crossover (%K above %D) is observed, potentially signaling an upward trend reversal or continuation. Stronger signal if this occurs below 50.
CCI (2025-12-17)
Commodity Channel Index
CCI (-71.85) is between -100 and 0. This indicates bearish momentum is present, but not yet extreme. A move below 0 from positive territory (bearish zero-line cross) can indicate a potential sell signal.
Volatility Measurement
ATR (2025-12-17)
Average True Range
Current ATR is 1.5500. ATR indicates average volatility. Market conditions are relatively stable.
Bollinger Bands (2025-12-17)
Volatility Bands
Current price (51.68) is within the Bollinger Bands (50.10 - 53.86). This suggests the price is trading within its typical volatility range. Price is below the Middle Band (51.98), indicating short-term bearish bias.
Risk Management & Potential Reversals (MIRM)
SAR (2025-12-17)
Parabolic Stop and Reverse
SAR points above price indicate bearish trend. Current SAR at 54.57 is 5.59% from price. Consider SAR as a potential take-profit level or to confirm a downtrend.
Stochastic (2025-12-17)
Approaching Oversold
Stochastic is approaching oversold territory (21.8). No reversal signal yet. Monitor for potential bullish crossover (K above D) or entry into oversold (20-) followed by reversal. Current crossover status: Bullish.
RSI (2025-12-17)
Reversal Perspective
Current RSI level is in neutral territory. No RSI divergence detected. Current RSI level doesn't suggest imminent reversal.
Bollinger Bands (2025-12-17)
Reversal Perspective
Bands show normal bandwidth. Price is in the middle of bands with normal bandwidth. No indication of imminent volatility expansion or reversal.
Holder List Top 20 (MIRM)
| Holder Name | Holder Type | Shares | Pct. Held | Date Reported |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | INSTITUTIONAL | 6795121 | 13.74% | 2025-03-31 |
| Janus Henderson Group PLC | INSTITUTIONAL | 4766109 | 9.64% | 2025-03-31 |
| Blackrock Inc. | INSTITUTIONAL | 3339557 | 6.75% | 2025-03-31 |
| BVF Inc. | INSTITUTIONAL | 2796513 | 5.65% | 2025-03-31 |
| Vanguard Group Inc | INSTITUTIONAL | 2540061 | 5.14% | 2025-03-31 |
| Eventide Asset Management LLC | INSTITUTIONAL | 2527000 | 5.11% | 2025-03-31 |
| Novo Holdings A/S | INSTITUTIONAL | 1500000 | 3.03% | 2025-03-31 |
| State Street Corporation | INSTITUTIONAL | 1494566 | 3.02% | 2025-03-31 |
| Citadel Advisors Llc | INSTITUTIONAL | 1445995 | 2.92% | 2025-03-31 |
| MUTUAL FUND SERIES TRUST-Eventide Gilead Fund | MUTUALFUND | 1430349 | 2.89% | 2025-03-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | MUTUALFUND | 1423701 | 2.88% | 2025-03-31 |
| Price (T.Rowe) Associates Inc | INSTITUTIONAL | 1415137 | 2.86% | 2025-03-31 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | MUTUALFUND | 1085995 | 2.2% | 2025-03-31 |
| iShares Trust-iShares Russell 2000 ETF | MUTUALFUND | 980281 | 1.98% | 2025-04-30 |
| T. Rowe Price New Horizons Fund, Inc. | MUTUALFUND | 757244 | 1.53% | 2025-03-31 |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | MUTUALFUND | 712399 | 1.44% | 2025-03-31 |
| Legg Mason Partners Investment Trust-ClearBridge Small Cap Growth Fund | MUTUALFUND | 691793 | 1.4% | 2025-01-31 |
| JANUS INVESTMENT FUND-Janus Henderson Triton Fund | MUTUALFUND | 687111 | 1.39% | 2025-03-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | MUTUALFUND | 626708 | 1.27% | 2025-03-31 |
| SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF | MUTUALFUND | 619920 | 1.25% | 2025-04-30 |